Asclera Resources for Healthcare Professionals
June 28 at 1:00pm CST
With guest speaker Jay Shuffler
July 5th at 6:30pm CST
1st Wednesday of every month until the end
of the year
NOTE: You will need to register for each webinar in order to view the recording of it.
- Sclerotherapy in Your Practice with Asclera Webinar from 6/22/2022
- Best Practices When Injecting Asclera Webinar from 8/17/2022
- The Patient Consult with Dr. Marlin Schul Webinar from 4/3/2023
Asclera® Injection was evaluated in a multicenter, randomized, double-blind, placebo and comparator-controlled trial (EASI-study) in patients with spider or reticular varicose veins. A total of 338 patients were treated with Asclera® (0.5% for spider veins [n=94], 1% for reticular veins [n=86], sodium tetradecyl sulfate [STS] 1% [n=105], or placebo [0.9% isotonic saline solution] [n= 53]) for either spider or reticular veins.
- Patients received an intravenous injection in the first treatment session; repeat injections were given 3 and 6 weeks later if the previous injection was evaluated as unsuccessful (defined as 1, 2, or 3 on a 5-point scale)
- Patients returned at 12 and 26 weeks after the last injection for final assessments. The primary effectiveness endpoint was improvement of veins judged by a blinded panel
- 95% of patients treated with Asclera® showed good improvement or complete treatment success as rated by the blinded panel*
- Asclera® treatment results were statistically significant when compared to placebo (p<0.0001) for the primary efficacy criterion “improvement of veins”
*Treatment success was rated by a blinded panel on a 5-point scale (1 = worse than before, 2 = same as before, 3 = moderate improvement, 4 = good improvement, 5 = complete treatment success).
Overview and Administration of Asclera
Ampule Opening and Drawing Into Syringe of Asclera
Sclerotherapy Procedure Set-up of Asclera
Patient Evaluation and Therapy of Asclera
Patient Post-Treatment Instructions of Asclera